Nature Reviews Immunology

Article	Citations
The trinity of COVID-19: immunity, inflammation and intervention	3042
A guide to cancer immunotherapy: from T cell basic science to clinical practice	2114
Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages	1796
COVID-19: immunopathology and its implications for therapy	1212
Viral targets for vaccines against COVID-19	799
COVID-19: the vasculature unleashed	772
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity	766
Immunological considerations for COVID-19 vaccine strategies	757
Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape	757
The cGAS–STING pathway as a therapeutic target in inflammatory diseases	720
A guide to vaccinology: from basic principles to new developments	694
T cell responses in patients with COVID-19	664
Considering how biological sex impacts immune responses and COVID-19 outcomes	639
Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19	582
Local and systemic mechanisms linking periodontal disease and inflammatory comorbidities	547
Neutralizing monoclonal antibodies for treatment of COVID-19	542
COVID-19 vaccines: modes of immune activation and future challenges	512
Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions?	432
Immunological mechanisms of vaccine-induced protection against COVID-19 in humans	421
The potential danger of suboptimal antibody responses in COVID-19	416
Tissue damage from neutrophil-induced oxidative stress in COVID-19	416
COVID-19 herd immunity: where are we?	392
Complement as a target in COVID-19?	389
Inflammation and immune dysfunction in Parkinson disease	368
BCG-induced trained immunity: can it offer protection against COVID-19?	359

Dysregulation of type I interferon responses in COVID-19	349
CD8+ T cell differentiation and dysfunction in cancer	345
The role of IgG Fc receptors in antibody-dependent enhancement	331
Lactate modulation of immune responses in inflammatory versus tumour microenvironments	325
Pre-existing immunity to SARS-CoV-2: the knowns and unknowns	321
The first 12 months of COVID-19: a timeline of immunological insights	316
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy	316
The type I interferon response in COVID-19: implications for treatment	302
Mucosal vaccines — fortifying the frontiers	287
COVID-19: risk for cytokine targeting in chronic inflammatory diseases?	278
The inflammatory pathogenesis of colorectal cancer	270
Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children	263
Metabolic barriers to cancer immunotherapy	243
Neutrophils in cancer: heterogeneous and multifaceted	236
In the eye of the COVID-19 cytokine storm	232
Not just antibodies: B cells and T cells mediate immunity to COVID-19	232
γδ T cells in tissue physiology and surveillance	231
Interferon-γ: teammate or opponent in the tumour microenvironment?	228
The roles of extracellular vesicles in the immune system	226
Fibroblasts as immune regulators in infection, inflammation and cancer	225
COVID-19: a case for inhibiting IL-17?	224
Redox regulation of immunometabolism	219
Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection	217
Cross-reactive memory T cells and herd immunity to SARS-CoV-2	216
Inflammasome activation at the crux of severe COVID-19	209
Regulation of immune responses by the airway epithelial cell landscape	207
Immunobiology and pathogenesis of hepatitis B virus infection	201
Dissecting antibody-mediated protection against SARS-CoV-2	200
Mitochondrial control of inflammation	196
SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact	196
Natural killer cells in antiviral immunity	194
Monkeypox: disease epidemiology, host immunity and clinical interventions	193
A guide to antigen processing and presentation	190
CD8+ T cell metabolism in infection and cancer	185
IL-17 and IL-17-producing cells in protection versus pathology	183
Targeting CD39 in cancer	182
Immune cell-mediated features of non-alcoholic steatohepatitis	173
Regulation of inflammation by the antioxidant haem oxygenase 1	172
How the immune system shapes atherosclerosis: roles of innate and adaptive immunity	169
GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches	167
Transcriptional regulation of memory B cell differentiation	163
Thymic development of unconventional T cells: how NKT cells, MAIT cells and γδ T cells emerge	162
Neuromodulation by the immune system: a focus on cytokines	162
The state of complement in COVID-19	158
The type I interferonopathies: 10 years on	156
Genetic models of human and mouse dendritic cell development and function	151
The germinal centre B cell response to SARS-CoV-2	148
Will SARS-CoV-2 variants of concern affect the promise of vaccines?	147
Constitutive immune mechanisms: mediators of host defence and immune regulation	146
Autoantibodies in neurological disease	144

Early life microbial exposures and allergy risks: opportunities for prevention	142
COVID-19 vaccine design: the Janus face of immune enhancement	141
How transcription factors drive choice of the T cell fate	139
Estimating disease severity of Omicron and Delta SARS-CoV-2 infections	138
A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion	136
Understanding COVID-19-associated coagulopathy	136
Innate immunity at the crossroads of healthy brain maturation and neurodevelopmental disorders	129
Immune ageing at single-cell resolution	125
Immunomodulation by endothelial cells — partnering up with the immune system?	124
Modulation of regulatory T cell function and stability by co-inhibitory receptors	124
Milder disease with Omicron: is it the virus or the pre-existing immunity?	122
Regulation of the nucleic acid-sensing Toll-like receptors	122
Macrophages: a Trojan horse in COVID-19?	121
Leukocyte trafficking to the lungs and beyond: lessons from influenza for COVID-19	120
Rethinking peripheral T cell tolerance: checkpoints across a T cell’s journey	120
Modulation of immune responses to vaccination by the microbiota: implications and potential mechanisms	115
Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses — are we our own worst enemy?	115
Roles of natural killer cells in immunity to cancer, and applications to immunotherapy	113
Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses	112
Death by TNF: a road to inflammation	111
Engineering IL-2 for immunotherapy of autoimmunity and cancer	110
Are COVID-19 vaccines safe in pregnancy?	109
Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models	106
Author Correction: Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages	105
Immune-mediated inflammatory disease therapeutics: past, present and future	105
Tissue regulatory T cells: regulatory chameleons	105
Glucocorticoids in T cell development, differentiation and function	103
Is IL-6 a key cytokine target for therapy in COVID-19?	101
NOD-like receptor-mediated plant immunity: from structure to cell death	101
The impact of the gut microbiome on extra-intestinal autoimmune diseases	99
TCF1 in T cell immunity: a broadened frontier	99
After 62 years of regulating immunity, dexamethasone meets COVID-19	99
Neuronal regulation of immunity: why, how and where?	98
The immunology of multiple sclerosis	98
Bacterial origins of human cell-autonomous innate immune mechanisms	97
T cell regeneration after immunological injury	96
SARS-CoV-2 infection and COVID-19 vaccination in pregnancy	96
Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?	92
Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies	89
Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination	87
The non-specific and sex-differential effects of vaccines	87
The role of T cells in age-related diseases	86
A guide to interrogating immunometabolism	85
Passive antibody therapy in COVID-19	85
Cellular networks controlling T cell persistence in adoptive cell therapy	83
Phase separation in immune signalling	82
Immunomodulation by anticancer cell cycle inhibitors	80
The precursors of CD8+ tissue resident memory T cells: from lymphoid organs to infected tissues	80
Omicron, the great escape artist	80
The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions?	79
Immunomodulation by radiotherapy in tumour control and normal tissue toxicity	78
Diversity and dynamism of IgA−microbiota interactions	77
Fighting COVID-19 exhausts T cells	76
Heterogeneity in the initiation, development and function of type 2 immunity	74
Host-directed immunotherapy of viral and bacterial infections: past, present and future	74
Neutrophil extracellular traps in systemic autoimmune and autoinflammatory diseases	74
The immunology of long COVID	73
Allergen immunotherapy: past, present and future	73
The spatio-temporal control of effector T cell migration	72
Myeloid cell-targeted therapies for solid tumours	71
Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases	69
Tissue-specific macrophages: how they develop and choreograph tissue biology	67
COVID-19 vaccines: neutralizing antibodies and the alum advantage	67
Clonal expansion of innate and adaptive lymphocytes	66
The interplay of immunology and cachexia in infection and cancer	65
Tuning immunity through tissue mechanotransduction	65
Lessons in self-defence: inhibition of virus entry by intrinsic immunity	62
Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection	61
Will we see protection or reinfection in COVID-19?	61
IL-9-producing T cells: potential players in allergy and cancer	60
Crosstalk between the renin–angiotensin, complement and kallikrein–kinin systems in inflammation	58
The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses	58
Functional categories of immune inhibitory receptors	58
DNA damage and repair in age-related inflammation	57
Endemic SARS-CoV-2 will maintain post-pandemic immunity	57
B cells in central nervous system disease: diversity, locations and pathophysiology	57
Will helminth co-infection modulate COVID-19 severity in endemic regions?	56
COVID-19 and cellular senescence	54
The link between circulating follicular helper T cells and autoimmunity	54
Innate immune detection of lipid oxidation as a threat assessment strategy	54

RHO GTPases: from new partners to complex immune syndromes	54
Can we harness the microbiota to enhance the efficacy of cancer immunotherapy?	54
T cell-oriented strategies for controlling the COVID-19 pandemic	53
Immune responses to human fungal pathogens and therapeutic prospects	53
Do cross-reactive antibodies cause neuropathology in COVID-19?	53
Immune and non-immune functions of adipose tissue leukocytes	52
Cerebral dysfunctions caused by sepsis during ageing	52
Omicron entry route	51
Understanding COVID-19 in Africa	51
Targeting IL-6 trans-signalling: past, present and future prospects	51
The role of chromatin loop extrusion in antibody diversification	51
Immunometabolism and HIV-1 pathogenesis: food for thought	51
Organellar homeostasis and innate immune sensing	49
Expanding dendritic cell nomenclature in the single-cell era	49
Keeping track of the SARS-CoV-2 vaccine pipeline	49
Building a T cell compartment: how immune cell development shapes function	49
Signals of hope: gauging the impact of a rapid national vaccination campaign	48
Role of thymic stromal lymphopoietin in allergy and beyond	48
Heterogeneity of type 2 innate lymphoid cells	47
The biology of TREM receptors	47
Blood clots and TAM receptor signalling in COVID-19 pathogenesis	46
Gasdermins: making pores for pyroptosis	46
Can we predict T cell specificity with digital biology and machine learning?	46
Severe COVID-19 in the young and healthy: monogenic inborn errors of immunity?	45
A call to arms: helping family, friends and communities navigate the COVID-19 infodemic	44
Advancing scientific knowledge in times of pandemics	44